

Freedom of Information Request	FOI 22-562	30 th November 2022
--------------------------------	------------	--------------------------------

I am researching the incidence and treatment of oesophageal and gastric cancer. I would greatly appreciate if you could answer the following questions.

The Health Board does not provide this treatment, all patients are referred to [Velindre University NHS Trust](#).

Q1. Please provide the total number of patients treated in the last 3 months with any systemic anti-cancer therapy for:

- **Oesophageal cancer (any type or stage)**
- **Oesophageal adenocarcinoma (any stage)**
- **Oesophageal squamous cell carcinoma (any stage)**
- **Gastric cancer (any type or stage)**
- **Cancer of the gastro-oesophageal junction (any stage)**

Q2. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- **CAPOX (Capecitabine with Oxaliplatin)**
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)**
- **Lonsurf (Trifluridine - tipiracil)**
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**

Q3. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)**
- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)**
- **Nivolumab monotherapy**
- **Nivolumab and Ipilimumab**
- **Any other systemic anti-cancer therapy**
- **Palliative care only**